SCHEMBL538070

SCHEMBL538070

Fc1cc2ccccc2nc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.55
ALDH1A1 P00352 5/20 0.52
MAPT P10636 5/20 0.52
GLA P06280 2/20 0.52
HPGD P15428 2/20 0.52
TDP1 Q9NUW8 2/20 0.52
ACHE P22303 1/20 0.52
MBNL1 Q9NR56 1/20 0.44
ALOX5 P09917 1/20 0.44
KDM4E B2RXH2 6/20 0.44
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
EGFR P00533 1/20 0.41
TOP2A P11388 1/20 0.41
TOP2B Q02880 1/20 0.41
PKM P14618 2/20 0.41
MEN1 O00255 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29911341 0.77 KMT2A (0.59) KMT2AALDH1A1MAPTGLAHPGD
SCHEMBL244868 0.77 KMT2A (0.59) KMT2AALDH1A1MAPTGLAHPGD
SCHEMBL2172354 0.77 ALDH1A1 (0.56) KMT2AALDH1A1MAPTGLAHPGD
SCHEMBL28643528 0.76 ALDH1A1 (0.54) KMT2AALDH1A1MAPTGLAHPGD
SCHEMBL538054 0.76 ALDH1A1 (0.54) KMT2AALDH1A1MAPTGLAHPGD
SCHEMBL31047153 0.76 ALDH1A1 (0.54) KMT2AALDH1A1MAPTGLAHPGD
SCHEMBL31278632 0.76 KMT2A (0.57) KMT2AALDH1A1MAPTGLAHPGD
SCHEMBL17993629 0.76 KMT2A (0.57) KMT2AALDH1A1MAPTGLAHPGD
SCHEMBL1067857 0.74 KDM4E (0.59) KMT2AALDH1A1MAPTGLAHPGD
SCHEMBL538069 0.74 ALDH1A1 (0.52) KMT2AALDH1A1MAPTGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0641341-B1 METHOD FOR PREPARING BENZO [b]NAPHTHYRIDINES RHONE POULENC RORER SA (FR) 2000-03-01 EP claimed
US-5484921-A Process for preparing benzo[b]naphthyridines LABORATOIRE ROGER BELLON (FR) 1996-01-16 US claimed
US-8598159-B2 Therapeutic pyrazoloquinoline derivatives DART NEUROSCIENCE (CAYMAN) LTD. (KY) 2013-12-03 US disclosed
EP-2166852-B1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES HELICON THERAPEUTICS INC (US) 2012-02-08 EP disclosed
US-20110065693-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES HELICON THERAPEUTICS, INC. (US) 2011-03-17 US disclosed
US-7872002-B2 Therapeutic pyrazoloquinoline derivatives HELICON THERAPEUTICS, INC. (US) 2011-01-18 US disclosed
CN-101742908-A therapeutic pyrazoloquinoline derivatives HELICON THERAPEUTICS INC 2010-06-16 CN disclosed
EP-2166852-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES Helicon Therapeutics, Inc. (US) 2010-03-31 EP disclosed
WO-2008154438-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES HELICON THERAPEUTICS, INC. (US) 2008-12-18 WO disclosed
US-20080306049-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES HELICON THERAPEUTICS, INC. (US) 2008-12-11 US disclosed
EP-0861864-B1 Method of preparation of polyquinolines HITACHI CHEMICAL CO LTD (JP) 2004-08-25 EP disclosed
US-5723573-A ACETYLENIC END GROUPS HITACHI CHEMICAL COMPANY, LTD. (JP) 1998-03-03 US disclosed
US-5648448-A Method of preparation of polyquinolines HITACHI CHEMICAL COMPANY, LTD. (JP) 1997-07-15 US disclosed
US-5484921-A Process for preparing benzo[b]naphthyridines LABORATOIRE ROGER BELLON (FR) 1996-01-16 US disclosed
US-5484921-A Process for preparing benzo[b]naphthyridines LABORATOIRE ROGER BELLON (FR) 1996-01-16 US disclosed
EP-0317188-B1 Heteroaromatic enamide derivatives and their use as pesticides ROUSSEL UCLAF (FR) 1995-09-27 EP disclosed
US-5442070-A Derivatives of fluoro-quinoline carboxylic-3-acid and preparation therefor LABORATOIRE ROGER BELLON (FR) 1995-08-15 US disclosed
EP-0538101-A1 Process for the preparation of benzo(b)naphthyridines LABORATOIRE ROGER BELLON (FR) 1993-04-21 EP disclosed
US-5114940-A Insecticides or anthelmintics from fused ring heterocycles containing amides or thioamides ROUSSEL-UCLAF (FR) 1992-05-19 US disclosed
EP-0317188-A2 Heteroaromatic enamide derivatives and their use as pesticides ROUSSEL UCLAF (FR) 1989-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306049-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES GABRA5, GABRB1, GABRB2 KMT2A 2970/4885ALDH1A1 587/4885MAPT 461/4885
US-20110065693-A1 THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES GABRA5, GABRB1, GABRB2 KMT2A 2970/4885ALDH1A1 587/4885MAPT 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.